2022
DOI: 10.3390/vaccines11010086
|View full text |Cite
|
Sign up to set email alerts
|

The BCG Moreau Vaccine Upregulates In Vitro the Expression of TLR4, B7-1, Dectin-1 and EP2 on Human Monocytes

Abstract: Background: Tuberculosis (TB) is currently the second greatest killer worldwide and is caused by a single infectious agent. Since Bacillus Calmette–Guérin (BCG) is the only vaccine currently in use against TB, studies addressing the protective role of BCG in the context of inducible surface biomarkers are urgently required for TB control. Methods: In this study, groups of HIV-negative adult healthy donors (HD; n = 22) and neonate samples (UCB; n = 48) were voluntarily enrolled. The BCG Moreau strain was used f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 79 publications
0
1
0
Order By: Relevance
“…Obtaining docking scores and biological activity data from online sources is difficult, because this is a specific and targeted study. Therefore, results showing the release of inflammatory cytokines directly related to the binding and activation of the mincle receptor were used [18].…”
Section: Discussionmentioning
confidence: 99%
“…Obtaining docking scores and biological activity data from online sources is difficult, because this is a specific and targeted study. Therefore, results showing the release of inflammatory cytokines directly related to the binding and activation of the mincle receptor were used [18].…”
Section: Discussionmentioning
confidence: 99%
“…In this connection, the immune response elicited during an in vitro model of monocyte stimulation with the BCG Moreau Vaccine is presented. The authors underscore the potential significance of biomarkers in immune stimulation and explore the role of the innate immune response in vaccine development and design [10].…”
mentioning
confidence: 99%